このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Lexicon Pharmaceuticals 過去の業績

過去基準チェック /06

Lexicon Pharmaceuticalsの収益は年間平均-42.8%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間15.5% 70.4%割合で減少しています。

主要情報

-50.2%

収益成長率

-41.7%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	-79.5%
株主資本利益率	-84.2%
ネット・マージン	-5,550.9%
前回の決算情報	30 Jun 2024

Recent updates

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Aug 03

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Apr 25

Does Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?

Jan 04

収支内訳

Lexicon Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:LXRX 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費
30 Jun 24	4	-202	136
31 Mar 24	2	-194	127
31 Dec 23	1	-177	114
30 Sep 23	1	-158	98
30 Jun 23	0	-131	78
31 Mar 23	0	-110	59
31 Dec 22	0	-102	48
30 Sep 22	0	-97	41
30 Jun 22	0	-97	35
31 Mar 22	0	-90	33
31 Dec 21	0	-88	32
30 Sep 21	0	-68	30
30 Jun 21	7	38	32
31 Mar 21	16	-13	38
31 Dec 20	24	-59	44
30 Sep 20	33	-104	52
30 Jun 20	320	39	57
31 Mar 20	321	85	57
31 Dec 19	322	130	57
30 Sep 19	330	164	59
30 Jun 19	43	-89	61
31 Mar 19	47	-101	63
31 Dec 18	63	-121	64
30 Sep 18	81	-126	63
30 Jun 18	101	-129	64
31 Mar 18	99	-130	66
31 Dec 17	92	-123	66
30 Sep 17	80	-133	64
30 Jun 17	81	-138	60
31 Mar 17	89	-141	50
31 Dec 16	79	-131	43
30 Sep 16	188	-22	36
30 Jun 16	160	-22	29
31 Mar 16	141	-11	27
31 Dec 15	130	-5	24
30 Sep 15	24	-94	21
30 Jun 15	24	-100	21
31 Mar 15	24	-98	19
31 Dec 14	23	-100	19
30 Sep 14	3	-115	19
30 Jun 14	3	-106	19
31 Mar 14	2	-109	18
31 Dec 13	2	-104	17

質の高い収益: LXRXは現在利益が出ていません。

利益率の向上: LXRXは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: LXRXは利益が出ておらず、過去 5 年間で損失は年間42.8%の割合で増加しています。

成長の加速: LXRXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: LXRXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: LXRXは現在利益が出ていないため、自己資本利益率 ( -67.01% ) はマイナスです。

Lexicon Pharmaceuticals 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Lexicon Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Lexicon Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

Lexicon Pharmaceuticals, Inc. to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

Lexicon Pharmaceuticals, Inc. Appoints Kristen L. Alexander as Its Principal Financial Officer

Lexicon Pharmaceuticals, Inc. Announces Post-Hoc Analysis of Phase 3 Data from the SCORED Clinical Trial

Consensus revenue estimates decrease by 41%

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Lexicon Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Lexicon Pharmaceuticals, Inc. Receives PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

Lexicon Pharmaceuticals, Inc. Publishes New Data Highlights Potential Cost-Savings of INPEFA®? (sotagliflozin) for Heart Failure

High number of new directors

Lexicon Pharmaceuticals, Inc. Announces Appointment of Mike Exton, Ph.D. as Chief Executive Officer

Lexicon Pharmaceuticals, Inc. Announces CEO Changes

Lexicon Pharmaceuticals, Inc. Announces That Data From it's RELIEF-DPN 1 Phase 2 Study of LX9211 Published in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Price target increased by 13% to US$6.20

Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much

New major risk - Shareholder dilution

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Lexicon Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024

Lexicon Pharmaceuticals, Inc., Annual General Meeting, May 10, 2024

Consensus revenue estimates decrease by 44%, EPS upgraded

Lexicon Pharmaceuticals, Inc. announced that it has received $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC, Artal International Management Sa, Artal International SCA, Artal Group S.A.

New major risk - Share price stability

Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Lexicon Pharmaceuticals, Inc. announced that it expects to receive $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC and other investors.

CEO & Director exercised options and sold US$161k worth of stock

Consensus revenue estimates fall by 54%

Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do

Lexicon Pharmaceuticals, Inc. Provides Business and Pipeline Update At 42nd Annual J.P. Morgan Healthcare Conference

Consensus revenue estimates decrease by 12%

Price target decreased by 7.2% to US$5.15

Lexicon Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain

Independent Director recently bought US$202k worth of stock

Consensus revenue estimates decrease by 31%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 30% to US$7.50

Lexicon Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Lexicon Pharmaceuticals, Inc. Appoints Lisa DeFrancesco as Head of Investor Relations and Corporate Strategy, Effective November 13, 2023

Lexicon Pharmaceuticals, Inc. Announces Data from Two Studies Demonstrating Positive Financial Impact of Inpefa (Sotagliflozin) to Be Presented At the Academy of Managed Care Pharmacy Nexus 2023 National Meeting

Independent Chairman of the Board recently bought US$1.1m worth of stock

Lexicon Pharmaceuticals, Inc. Announces the Retirement of Alan S. Nies from Board of Directors, Effective October 26, 2023

New minor risk - Share price stability

Lexicon Pharmaceuticals, Inc. Receives Preferred Formulary Status with Express Scripts for Medicare Patients

Lexicon Pharmaceuticals, Inc. to Present Study Results Relating to Sotagliflozin and Lx9211 At the 59Th Annual Meeting of the European Association for the Study of Diabetes

Consensus EPS estimates fall by 18%

Lexicon Pharmaceuticals, Inc. Announces Published Analysis of Sotagliflozin Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexicon Pharmaceuticals, Inc. Elects Diane E. Sullivan to Its Board of Directors

Lexicon Pharmaceuticals, Inc. Announces Resignation of Frank P. Palantoni from Board of Directors, Effective July 27, 2023

CEO & Director recently bought US$92k worth of stock

Lexicon Pharmaceuticals, Inc. Presents Study Results Relating to LX9211 and INPEFA (Sotagliflozin) At the American Diabetes Association’s 83rd Scientific Sessions

Lexicon Pharmaceuticals, Inc. Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure

Lexicon Pharmaceuticals, Inc. announced that it has received $72.21513 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. announced that it has received $62.795767 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. announced that it expects to receive $62.795767 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $62.204233 million.

Lexicon Pharmaceuticals, Inc. Announces Fda Approval of Inpefa™ (Sotagliflozin) for Treatment of Heart Failure

Consensus revenue estimates increase by 31%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Consensus EPS estimates fall by 13%

Full year 2022 earnings: EPS and revenues miss analyst expectations

CEO & Director exercised options and sold US$111k worth of stock

Does Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?

Lexicon Pharmaceuticals, Inc. Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia

過去基準チェック /06